11:25 AM EDT, 04/04/2024 (MT Newswires) -- CureVac ( CVAC ) said Thursday that interim data from an ongoing phase 2 part of a combined phase 1/2 study showed that its multivalent influenza vaccine candidate boosted antibody titers against all four encoded flu strains and has an "acceptable" safety and tolerability profile.

The company said the multivalent vaccine candidate, which was selected from the candidates tested in phase 1, boosted antibody titers across all age groups and tested dose levels, including the lowest tested dose.

CureVac ( CVAC ) also said majority of the reported adverse events were either mild or moderate within seven days of dosing.

The company is collaborating with GSK (GSK) for the seasonal influenza vaccine development program, which tests vaccine candidates using CureVac's ( CVAC ) second-generation mRNA backbone.

CureVac ( CVAC ) shares were up 1.4% in recent trading.

Price: 2.95, Change: +0.04, Percent Change: +1.37